Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
A phase 3 trial of Gamma Knife in Pituitary tumours, run by Samsung Medical Center, with a status the registry has not verified recently.
Overview
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma is a phase 3 interventional study registered as NCT03439709 by Samsung Medical Center, with 90 participants planned, started 2018-03-01 and due to reach its primary completion in 2022-06-30. Interventions recorded: Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection. Conditions recorded: Acromegaly Due to Pituitary Adenoma.
Linked to the technology Gamma Knife because the registry names it ("gamma knife") among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma
Shares Gamma Knife and the tag pipeline.
- TrialPhase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
Shares Gamma Knife and the tag pipeline.
- TrialSafety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStudy of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStrict IGF-1 Control in Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialCabergoline in Nonfunctioning Pituitary Adenomas
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Potency of a High Cabergoline Dosage in Microprolactinomas
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.